The U.S. Drug Enforcement Agency (DEA) has notified GW Pharmaceuticals (NASDAQ:GWPH) that it no longer considers Epidiolex (cannabidiol) a controlled substance. The change is effective immediately.
The move was expected. In September 2018, the DEA took the intermediate step of categorizing the
product as a Schedule 5 drug (includes cough suppressants that contain
modest amounts of codeine, Lyrica and Motofen) that have lower abuse
potential than Schedule 4 substances (i.e., Xanax, Darvon, Ambien).
Shares up 4% premarket on light volume.
https://seekingalpha.com/news/3558584-gw-pharmas-epidiolex-descheduled-dea
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.